From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours
Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only cur...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/81 |
| _version_ | 1828074791922302976 |
|---|---|
| author | Emilio Bajetta Giuseppe Procopio Sara Pusceddu Filippo Pietrantonio Massimo Milione Marco Maccauro Elena Verzoni Valentina Guadalupi Marco Platania |
| author_facet | Emilio Bajetta Giuseppe Procopio Sara Pusceddu Filippo Pietrantonio Massimo Milione Marco Maccauro Elena Verzoni Valentina Guadalupi Marco Platania |
| author_sort | Emilio Bajetta |
| collection | DOAJ |
| description | Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage. |
| first_indexed | 2024-04-11T01:49:16Z |
| format | Article |
| id | doaj.art-dec52cdc00d240d69508ff2a664c2ff3 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:49:16Z |
| publishDate | 2011-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-dec52cdc00d240d69508ff2a664c2ff32023-01-03T07:01:12ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-12-013210.4081/oncol.2009.7975From biology to clinical experience: evolution in the knowledge of neuroendocrine tumoursEmilio Bajetta0Giuseppe Procopio1Sara Pusceddu2Filippo Pietrantonio3Massimo Milione4Marco Maccauro5Elena Verzoni6Valentina Guadalupi7Marco Platania8Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanPathology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, MilanNuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanMedical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, MilanNeuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.http://www.oncologyreviews.org/index.php/or/article/view/81Neuroendocrine tumours - Angiogenesis - Metastasis - Chemotherapy - Target therapy |
| spellingShingle | Emilio Bajetta Giuseppe Procopio Sara Pusceddu Filippo Pietrantonio Massimo Milione Marco Maccauro Elena Verzoni Valentina Guadalupi Marco Platania From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours Oncology Reviews Neuroendocrine tumours - Angiogenesis - Metastasis - Chemotherapy - Target therapy |
| title | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_full | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_fullStr | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_full_unstemmed | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_short | From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours |
| title_sort | from biology to clinical experience evolution in the knowledge of neuroendocrine tumours |
| topic | Neuroendocrine tumours - Angiogenesis - Metastasis - Chemotherapy - Target therapy |
| url | http://www.oncologyreviews.org/index.php/or/article/view/81 |
| work_keys_str_mv | AT emiliobajetta frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT giuseppeprocopio frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT sarapusceddu frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT filippopietrantonio frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT massimomilione frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT marcomaccauro frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT elenaverzoni frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT valentinaguadalupi frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours AT marcoplatania frombiologytoclinicalexperienceevolutionintheknowledgeofneuroendocrinetumours |